China Sets Up Committee For Pharmaceutical Research Intellectual Property Rights
This article was originally published in PharmAsia News
Executive SummaryChinese Pharmaceutical Association's Committee for Pharmaceutical Research Intellectual Property Rights, the first professional organization in the field, recently held its first plenary meeting in Beijing. The committee was set up with the objectives of bridging communication among authorities, societies, pharmaceutical enterprises and public institutions; providing advice on IP rights strategy for the nation, pharmaceutical industry and enterprises; and offering consultations for China's decision makers. Its role will be to promote the establishment of a scientific, rational and strict pharmaceutical IP rights system to support pharmaceutical innovation; provide advice for the industry and government by initiating research on TCM IP rights in international trading; and groom technical expertise in a planned and systematic way. (Click here for more - Chinese language)
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.